Related Experiment Videos
Drug therapy for prevention of cardiovascular disease--should surrogate measures be abandoned?
1Department of Diabetes and Endocrinology, Queen Elizabeth II Hospital, Howlands, Welwyn Garden City, Herts. peter.winocour@nhs.net
Insights
Fixed doses of cardiovascular disease therapies may lead to over-interpretation and inappropriate use. Individualized risk factor measurement and treatment optimization are crucial for effective cardiovascular disease management.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Current strategies for cardiovascular disease (CVD) reduction often involve fixed-dose therapies for hypertension, dyslipidemia, and platelet aggregation.
- Clinical outcome studies, while demonstrating broad benefits, may lead to over-interpretation and misapplication of findings to diverse individual patient populations.
- The efficacy of fixed-dose statins for dyslipidemia and the unique benefits of ACE inhibitors/ARBs are debated, with potential for drug interactions to attenuate benefits.
Purpose of the Study:
- To critically evaluate the evidence supporting fixed-dose therapies for cardiovascular disease (CVD) risk reduction.
- To highlight the potential limitations and risks associated with the widespread application of standardized treatment protocols.
- To advocate for a return to individualized patient assessment and management strategies for CVD risk factors.
Main Methods:
- Review of clinical outcome studies on antihypertensive, hypolipidemic, and antiplatelet therapies.
- Analysis of data regarding the efficacy and safety of fixed-dose versus individualized treatment approaches.
- Examination of clinical experience with specific drug classes, including statins and renin-angiotensin system modulators.
Main Results:
- Evidence suggests that fixed-dose therapies may not be optimal for all patients, potentially leading to over-interpretation of study results and inappropriate use.
- Studies show contradictory findings regarding non-hypotensive benefits of certain agents, and suboptimal control of mild hypertension is common.
- Clinical experience indicates reduced efficacy and increased adverse events, such as renal function deterioration, with fixed-dose therapies in specific patient groups (e.g., hypertensive diabetic renal disease).
Conclusions:
- Widespread application of fixed-dose CVD therapies risks inappropriate use and adverse effects.
- Individualized measurement of CVD risk factors and tailored treatment approaches are essential for optimal patient care.
- Pragmatic individualization of care, including dose optimization and monitoring, should remain the cornerstone of managing asymptomatic CVD risk factors.
Abstract:
It has been suggested that the most effective method of reducing cardiovascular disease (CVD) is to define overall CVD risk and apply fixed doses of anti-hypertensive, hypolipidaemic and anti-platelet therapies, using the evidence base from clinical outcome studies. Such studies have examined large numbers of patients with a wide representation of subgroups and demon-Welwyn strated equivalent benefits in all subsets. In so doing, there may be over-interpretation of the data leading to large-scale applicability of the findings to individuals who were not genuinely represented in the study populations. Most lipid-lowering studies have been unable to consider the possibility that optimal correction of dyslipidaemia would have been more effective than the use of a fixed dose of statins. Studies of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockade have produced contradictory findings regarding unique non-hypotensive beneficial CVD effects, and suboptimal control of mild hypertension was a frequent finding in the study populations. Scrutiny of concomitant therapy in studies that focus on a particular issue such as LDL (low-density lipoprotein) cholesterol or blood pressure supports the notion that benefits from the agent may be attenuated by other drugs. Widespread application of fixed doses of all these agents to at-risk cases will increase the incidence of inappropriate use and side effects. Clinical experience with modulators of the renin-angiotensin system in hypertensive diabetic renal disease confirms reduced efficacy, and more frequent deterioration of renal function than observed in clinical trials. Measurement of individual biomedical CVD risk factors along with overall risk estimation should continue to be the mainstay of clinical practice. This will allow appropriate case selection for different agents, optimisation of dosage or better assessment of compliance where treatment is less efficacious, and monitoring for adverse effects of therapy. Pragmatic individualisation of care should remain the basis for treating asymptomatic CVD risk factors.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:27Peripheral Artery Disease III: Interprofessional Care